NEW YORK – Investigators hopeful about bringing liquid biopsy into the clinical care of brain cancer patients have published new data showing that imaging methods can help predict which glioblastoma patients can be successfully genotyped using a blood-based assay, and which cannot.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
